(2-((叔丁氧基羰基)氨基)乙基)噁唑-4-羧酸 | 1216000-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (2-((叔丁氧基羰基)氨基)乙基)噁唑-4-羧酸
• 英文名称: 2-(2-{[(tert-butoxy)carbonyl]amino}ethyl)-1,3-oxazole-4-carboxylic acid
• 英文别名: 2-(2-((Tert-butoxycarbonyl)amino)ethyl)oxazole-4-carboxylic acid；2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]-1,3-oxazole-4-carboxylic acid
• CAS: 1216000-01-9
• 化学式: C₁₁H₁₆N₂O₅
• 分子量: 256.258
• InChiKey: LZOVRFNJESHFCK-UHFFFAOYSA-N

物化性质

• 沸点：
  433.1±25.0 °C(Predicted)
• 密度：
  1.245±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2-((叔丁氧基羰基)氨基)乙基)噁唑-4-羧酸 在 盐酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 52.0h， 生成 2-(2-aminoethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide dihydrochloride
  参考文献：
  名称：

  [EN] FERROPORTIN INHIBITORS
  [FR] NOUVEAUX INHIBITEURS DE LA FERROPORTINE

  摘要：

  公开号：

  WO2017068089A9

文献信息

• Ferroportin inhibitors
  申请人：Vifor (International) AG

  公开号：US10364239B2

  公开（公告）日：2019-07-30

  The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

  本发明涉及通式(A-I)的新型化合物，其中Het-2为通式(AA)的任选取代的双环杂芳基。本发明涉及由这些化合物组成的药物组合物及其作为药物的用途，特别是作为铁皮质素抑制剂的用途，尤其是用于预防和/或治疗由缺乏铁皮质素或铁代谢紊乱引起的疾病，如特别是铁过载状态，如地中海贫血症和血色病。
• FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3364967A2

  公开（公告）日：2018-08-29
• NOVEL FERROPORTIN INHIBITORS
  申请人：Vifor (International) AG

  公开号：EP3365339A1

  公开（公告）日：2018-08-29
• Novel Ferroportin Inhibitors
  申请人：Vifor (International) AG

  公开号：US20180297991A1

  公开（公告）日：2018-10-18

  The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
• [EN] NOVEL FERROPORTIN INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE LA FERROPORTINE
  申请人：VIFOR (INTERNATIONAL) AG

  公开号：WO2017068089A2

  公开（公告）日：2017-04-27

  The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.